Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders - PubMed (original) (raw)
Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders
G J Locker et al. Br J Haematol. 1999 Jun.
Free article
Abstract
Treatment with intravenous recombinant human interleukin-2 (rh IL-2) is frequently accompanied by the capillary leak syndrome and disturbances of the coagulation system. Although the exact mechanisms are still not fully understood, the involvement of the endothelium is proven. This investigation aimed to elucidate more precisely the role of the endothelium in the generation of IL-2-based side-effects. In nine tumour patients receiving intravenous rh IL-2, parameters characterizing endothelial cell activation as well as activation of the coagulation system were evaluated. A significant increase of the circulating endothelial leucocyte adhesion molecule-1 (cELAM-1) and the vasoconstrictor peptide endothelin-1 (ET-1) was observed (P<0.05), indicating activation of endothelial cells. The simultaneous increase of tissue-plasminogen activator and plasminogen activator inhibitor type-1 during therapy (P<0.05) corroborated this observation. A decrease in platelet count parallelled by an increase of fibrin degradation products, the prolongation of partial thromboplastin time, and the decrease of fibrinogen (P<0.05) suggested the development of disseminated intravascular coagulation (DIC), induced by activated endothelium and intensified by transient hepatic failure. We concluded that activation of the endothelium mediated by IL-2 was accompanied by a loss of endothelial integrity and capillary leak. The activated endothelium can trigger DIC via activation of the coagulation cascade. The increased ET-1 might act as an endogenous counter-regulator of the disadvantageous haemodynamic side-effects induced by IL-2.
Similar articles
- Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome.
Cotran RS, Pober JS, Gimbrone MA Jr, Springer TA, Wiebke EA, Gaspari AA, Rosenberg SA, Lotze MT. Cotran RS, et al. J Immunol. 1988 Mar 15;140(6):1883-8. J Immunol. 1988. PMID: 3279124 - Activation of endothelial and coagulation systems in left ventricular assist device recipients.
John R, Panch S, Hrabe J, Wei P, Solovey A, Joyce L, Hebbel R. John R, et al. Ann Thorac Surg. 2009 Oct;88(4):1171-9. doi: 10.1016/j.athoracsur.2009.06.095. Ann Thorac Surg. 2009. PMID: 19766802 - The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6.
Kruithof EK, Mestries JC, Gascon MP, Ythier A. Kruithof EK, et al. Thromb Haemost. 1997 May;77(5):905-10. Thromb Haemost. 1997. PMID: 9184401 - Infections and endothelial cells.
Keller TT, Mairuhu AT, de Kruif MD, Klein SK, Gerdes VE, ten Cate H, Brandjes DP, Levi M, van Gorp EC. Keller TT, et al. Cardiovasc Res. 2003 Oct 15;60(1):40-8. doi: 10.1016/s0008-6363(03)00354-7. Cardiovasc Res. 2003. PMID: 14522405 Review.
Cited by
- Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer.
Wang X, Guo Z, Wu X, Chen D, Wang F, Yang L, Luo M, Wu S, Yang C, Huang L, Fu L. Wang X, et al. Immunotargets Ther. 2023 Jan 4;12:1-16. doi: 10.2147/ITT.S373866. eCollection 2023. Immunotargets Ther. 2023. PMID: 36632330 Free PMC article. - A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.
Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL. Ozkaynak MF, et al. Front Immunol. 2018 Jun 18;9:1355. doi: 10.3389/fimmu.2018.01355. eCollection 2018. Front Immunol. 2018. PMID: 29967609 Free PMC article. - Biomarker Profile of Sepsis-Associated Coagulopathy Using Biochip Assay for Inflammatory Cytokines.
Walborn A, Hoppensteadt D, Syed D, Mosier M, Fareed J. Walborn A, et al. Clin Appl Thromb Hemost. 2018 May;24(4):625-632. doi: 10.1177/1076029617709084. Epub 2017 May 17. Clin Appl Thromb Hemost. 2018. PMID: 28514870 Free PMC article. - Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.
Lechner MG, Russell SM, Bass RS, Epstein AL. Lechner MG, et al. Immunotherapy. 2011 Nov;3(11):1317-40. doi: 10.2217/imt.11.115. Immunotherapy. 2011. PMID: 22053884 Free PMC article. Review. - Innate immune natural killer cells and their role in HIV and SIV infection.
Bostik P, Takahashi Y, Mayne AE, Ansari AA. Bostik P, et al. HIV Ther. 2010 Jul 1;4(4):483-504. doi: 10.2217/HIV.10.28. HIV Ther. 2010. PMID: 20730028 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical